Application 022407
- Type
- NDA
- Sponsor
- THERAVANCE INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | VIBATIV | TELAVANCIN | INJECTABLE; INJECTION | 250MG | No | No |
| 002 | VIBATIV | TELAVANCIN | INJECTABLE; INJECTION | 750MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| VIBATIV | TELAVANCIN HYDROCHLORIDE | Cumberland Pharmaceuticals Inc. | 5359b759-db7c-4672-9e8a-59c93869bd91 | 2025-12-19 | Boxed warning, Warnings, Adverse reactions | VIBATIV |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.